Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Upper Facial Lines
Interventions: BOTOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Vista, California + 4 more

Conditions: Chronic Pain, Adults 21 and Older, Multiple Chronic Overlapping Pain Conditions, Hypersensitivity
Interventions: High Intensity Quell, Low Intensity Quell; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 99 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: CPG 7909, Chemotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 17
States / cities: Gilroy, California • Los Angeles, California • Palm Springs, California + 14 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 60
States / cities: Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more

Conditions: Chronic Kidney Disease, Dialysis, Hyperphosphatemia
Interventions: MCI-196, Placebo; Drug
Lead sponsor: Tanabe Pharma Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 38
States / cities: Glendale, Arizona • Tempe, Arizona • Hot Springs, Arkansas + 35 more

Conditions: Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: pegaptanib sodium injection; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 50 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 4
States / cities: Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more

Conditions: Prostate Cancer
Interventions: SU011248; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Degenerative Disc Disease
Interventions: ILIF; Procedure
Lead sponsor: NuVasive; Industry
Eligibility: 40 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 8
States / cities: Phoenix, Arizona • Santa Monica, California • Gainesville, Florida + 5 more

Conditions: Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma, Medullary Thyroid Carcinoma
Interventions: 225Ac-ETN029, 111In-ETN029; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Alzheimer's Disease
Interventions: Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 93
States / cities: Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more

Conditions: Epilepsy
Interventions: Lacosamide; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 1 Month to 18 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Orlando, Florida • Henderson, Nevada + 3 more

Conditions: Metatarsal Fracture
Interventions: AccelStim (LIPUS); Device
Lead sponsor: Orthofix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Evanston, Illinois • Mount Prospect, Illinois • Laurel, Maryland

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
Interventions: PRT7732; Drug
Lead sponsor: Prelude Therapeutics Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 11
States / cities: San Francisco, California • Detroit, Michigan • New York, New York + 7 more

Conditions: Hypertension, Hypercholesterolemia, Dyslipidemia
Interventions: Valsartan and simvastatin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Chlorhexidine gluconate; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 13 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more

Conditions: Diabetic Foot Ulcer
Interventions: Not listed
Lead sponsor: Solsys Medical LLC; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Washington, Pennsylvania • Newport News, Virginia

Conditions: Recurrent or Metastatic Breast Cancer
Interventions: DHP107, IV Paclitaxel; Drug
Lead sponsor: Daehwa Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Boca Raton, Florida + 8 more

Conditions: Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
Interventions: nab-sirolimus; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Newport Beach, California • Denver, Colorado • Dallas, Texas + 1 more

Conditions: Prostate Cancer
Interventions: Invitae multi-cancer gene panel; Diagnostic Test
Lead sponsor: Invitae Corporation; Industry
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 19
States / cities: San Diego, California • San Francisco, California • Lakewood, Colorado + 13 more

Conditions: Hypertension
Interventions: Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more

Conditions: Papulopustular Rosacea
Interventions: S5G4T-1, S5G4T-2; Drug
Lead sponsor: Sol-Gel Technologies, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hepatitis C, Chronic
Interventions: Sofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 42
States / cities: Montgomery, Alabama • Bakersfield, California • Coronado, California + 33 more

Conditions: Alzheimer's Disease
Interventions: PPI-1019 (APAN); Drug
Lead sponsor: PRAECIS Pharmaceuticals Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: San Juan Capistrano, California

Search by objective public record fields.

A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

Efficacy of the Quell Wearable Device for Chronic Overlapping Pain Conditions

CPG 7909 Injection in Non-Small Cell Lung Cancer

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy

An Evaluation of Interlaminar Lumbar Instrumented (ILIF™)

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

A Data Collection Protocol to Evaluate the Real World Usage of the Orthofix AccelStim Device to Treat Fresh Metatarsal Fractures

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin

The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients

Multi Center Site , Controlled Trial Comparing a Bioengineered Skin Substitute to a Human Skin Allograft

Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection

Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease